These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12797387

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans.
    St-Germain G, Dion C.
    Mycoses; 1996; 39(5-6):201-6. PubMed ID: 8909030
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
    Mahabeer Y, Chang CC, Naidu D, Dorasamy A, Lewin S, Ndung'u T, Moosa MY, French M, Mlisana K, Coovadia Y.
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT, Mouton JW, van den Beukel CJ, van der Lee HA, Meis JF, Verweij PE.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
    Barchiesi F, Schimizzi AM, Najvar LK, Bocanegra R, Caselli F, Di Cesare S, Giannini D, Di Francesco LF, Giacometti A, Carle F, Scalise G, Graybill JR.
    Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
    [Abstract] [Full Text] [Related]

  • 14. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.
    Block ER, Bennett JE.
    Proc Soc Exp Biol Med; 1973 Feb; 142(2):476-80. PubMed ID: 4570039
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 17. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [Abstract] [Full Text] [Related]

  • 18. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
    Poon M, Cronin DC, Wormser GP, Bottone EJ.
    Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
    [Abstract] [Full Text] [Related]

  • 19. Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.
    te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3341-6. PubMed ID: 16048945
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.